We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning (Review).
- Authors
HARUKO IRIE; KOUJI BANNO; MEGUMI YANOKURA; MIHO IIDA; MASATAKA ADACHI; KANAKO NAKAMURA; KIYOKO UMENE; YUYA NOGAMI; KENTA MASUDA; YUSUKE KOBAYASHI; EIICHIRO TOMINAGA; DAISUKE AOKI
- Abstract
Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.
- Subjects
METFORMIN; HYPOGLYCEMIC agents; GYNECOLOGIC cancer; CANCER in women; GLIOMA treatment; BREAST cancer treatment
- Publication
Oncology Letters, 2016, Vol 11, Issue 2, p1287
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2016.4075